Harrison's Principles of Internal Medicine, Ninth Edition,: “Section 8: Alterations in Reproductive and Sexual Function—Sub-Section 47: Disturbances of Sexual Function and Reproduction in Men”, eds.: Isselbacher et al., New York: McGraw-Hill Book Compa.* |
Segraves, “Effects of Psychotrophic Drugs on Human Erection and Ejaculation,” Arch. Gen. Psychiatry, vol. 46, <arch 1989, pp. 275-284.* |
Samarthji Lal, et al., Apomorphine-Induced Penile Tumescence in Impotent Patients-Preliminary Findings, 1987 Prog. Neuro-Pshychoparmacol & Biol. Psychiat., vol., II, pp. 235-242. |
Jeremy P. W. Heaton, M.D., et al., Recovery of Erectile Function by the Oral Administration of Apomorphine, Feb. 1995, Urology, vol. 45, No. 2, pp. 200-206. |
I. Goldstein and JR Berman, Vasculogenic Female Sexual Dysfuction: Vaginal Engorgement and Clitoral Erectile Insufficiency Syndromes, International Journal of Impotence Research (1998) 10, Suppl 2, pp. S84-S90. |
R.T. Segraves, Editorial: Pharmacological Era in the Treatment of Sexual Disorders, (1998) Journal of Sex & Marital Therapy, vol. 24, pp. 67-68. |
Tagliamonte et al., Pharm. Biochem. and Behavior vol. 2, pp. 257-260 (1974). |
Laduron et al., Biochem. Pharmacology, vol. 28, pp. 2161-2165 (1979). |
Baldessarini et al., in Gessa et al., eds., Apomorphine & Other Dopaminomimetics, vol. 1, Basic Pharmacology, pp. 219-288 (1981). |
Lal et al., J. Neural Transmission, vol. 54, pp. 75-84 (1982). |
Reynolds, James E. F., ed., Martindale, 28th Edition, pp. 891-892 (1982). |
Gower et al., European J. of Pharmacology, vol. 122, pp. 239-244 (1986). |
Melis et al., Brain Research, vol. 415, 98-104 (1987). |
Segraves et al., Archives of Sexual Behavior, vol. 16, No. 2, pp. 125-137 (1987). |
Danjou et al., Br.J. Clin. Pharmac., vol. 26, pp. 733-739 (1988). |
Lal S., Prog. Neuro-Psychopharm. & Biol. Psych., vol. 12, pp. 117-164 (1988). |
Pehek et al., Pharm. Biochem. and Behavior 31:201-208 (1988). |
Danjou et al., J. Pharamacol. Methods, vol. 21, pp. 61-69 (1989). |
Gancher et al., AM. Neurol., vol. 26, pp. 232-238 (1989). |
Segraves R. T., Arch. Gen. Psych., vol. 46, pp. 275-284 (1989). |
Durif et al., Eur. J. Clin. Pharmacology, vol. 41, pp. 493-494 (1991). |
Essink et al., J. Chromatography, vol., 570, pp. 419-424 (1991). |
Gancher et al., Movement Disorders, vol. 6, No. 3, pp. 212-216 (1991). |
Heaton et al., J. Urology, vol. 145, pp. 192-194 (1991). |
Heaton et al., J. Urology, vol. 145, pp. 1099-1102 (1991). |
Lal et al., J. Psych. Neurosci., vol. 16, No. 5, pp. 262-266 (1991). |
Montastruc et al., Clin. Neuropharmacology, vol. 14, No. 5, pp. 432-437 (1991). |
Panegyres et al., Med. J. Australia, vol. 155, pp. 371-374 (1991). |
Segraves et al., J. Urology, vol. 145, pp. 1174-1175 (1991). |
Durif et al., Clinical Neuropharmacology, vol. 16, No. 2, pp. 157-166 (1993). |
Heaton et al., J. Urology, vol. 151, pp. 797-800 (1994). |
Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, pp. 225-229 (1995). |
Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, 9th Edition, pp. 4-9 (1996). |